RC220 inhibits FTO very well. I think what they mean by the m6A mRNA opportunity is diseases other than cancer, where a lower toxicity profile is required.
[INTERVIEW] Breaking Barriers in Cancer Treatment: Race Oncology Pioneers a New Era with Bisantrene, page-56
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.77 |
Change
0.015(0.86%) |
Mkt cap ! $300.6M | |||
| Open | High | Low | Value | Volume |
| $1.82 | $1.82 | $1.77 | $91.78K | 51.30K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 31147 | $1.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.80 | 8318 | 1 |
View Market Depth
| Last trade - 15.59pm 10/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |